Using multiple patient datasets with expression profiles and clinicopathological information, we also found that TGF-β and higher KLF5 expression correlated with poor prostate cancer patient survival; and showed that BCL2 was a potential biomarker with both prognostic and predictive functions. Here, KLF5 is linked to Familial prostate cancer.